CAMBRIDGE, Mass.--(Foundation Medicine, Inc., a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis to routine clinical care, today announced a strategic pilot collaboration with Novartis to develop, enhance and optimize Foundation Medicine’s cancer genome panel test for Novartis’ needs. If the pilot phase is successful, Novartis and Foundation Medicine will evaluate opportunities to collaborate on the production and commercialization of the test. Financial details of the agreement were not disclosed.)--
“This pilot collaboration with Novartis represents our first pharmaceutical partnership, and we are delighted to accomplish this important milestone with one of the world’s leading cancer therapeutic companies”
“This pilot collaboration with Novartis represents our first pharmaceutical partnership, and we are delighted to accomplish this important milestone with one of the world’s leading cancer therapeutic companies,” said Alexis Borisy, chief executive officer, Foundation Medicine. “As part of this agreement, Foundation will leverage the broad contents and high quality of our cancer genome analysis platform. By delivering a clinical-grade analysis of molecular information, Foundation’s dedicated clinical research team will help our partners more rapidly translate novel findings into therapeutically applicable results. This collaboration is an important step forward for Foundation and could provide us with the basis for building successful cancer genome analysis platforms for future collaborations and partners.”
About Foundation Medicine
Foundation Medicine was launched in April 2010 and is focused on developing clinical laboratory tests – using next generation sequencing and other advanced technologies – that will broadly analyze the relevant tumor genomic and other molecular information present in individual patients’ cancers. The results will be delivered to oncologists in an easily accessible format, within the context of a growing knowledge base of published clinical data to help oncologists personalize treatment. The company’s founding academic advisors – from the Broad Institute, the Dana Farber Cancer Institute, Harvard Medical School and the Massachusetts Institute of Technology – are world leaders in the fields of cancer genomics, cancer biology, clinical oncology and information sciences. They, alongside biotechnology and molecular diagnostics industry leaders, possess the multi-disciplinary expertise required to bring cancer genomics into the routine practice of medicine.
Foundation Medicine is dedicated to the development of comprehensive tests that will help physicians personalize cancer treatment for their patients. Foundation Medicine’s laboratory tests are designed to accommodate and assimilate a dynamic landscape of cancer genome and other molecular information and growing availability of treatment options. These tests will help oncologists make prompt and informed determinations about the best cancer treatment for each patient, taking into account the patient’s unique cancer-associated aberrations against relevant genomic insights and therapeutic approaches. The company’s founding advisors are world leaders in genome technology, cancer biology and clinical oncology. They, alongside biotech and molecular diagnostics industry leaders, will harness emerging technologies to develop unparalleled tests that identify and interpret an ever-growing set of actionable genomic and other molecular alterations, truly enabling personalized cancer medicine. For more information, please visit the company’s website at www.foundationmedicine.com.